Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A nonapeptide (9 amino acids) first isolated from rabbit cerebral venous blood in 1977. Originally studied for sleep-induction properties, it is now being investigated for opioid withdrawal and chronic insomnia.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Studied for telomere lengthening, melatonin regulation, and anti-aging properties.
Modulates the sleep-wake cycle through interactions with opioid, serotonin, and other neurotransmitter systems. Reduces the activity of stress-response systems. Mechanism is not fully characterized, but effects appear to be on circadian regulation and stress adaptation.
Stimulates the pineal gland to increase melatonin production. Activates telomerase, an enzyme that maintains telomere length, potentially slowing cellular aging. Also reported to normalize circadian rhythms and modulate neuroendocrine function.
- Sleep quality improvement
- Opioid withdrawal support
- Stress and cortisol reduction
- Chronic insomnia
- Narcolepsy (investigational)
- Anti-aging and longevity protocols
- Improved sleep quality
- Telomere length maintenance
- Cancer prevention (preliminary research)
- Circadian rhythm regulation
- Limited human clinical data
- Mechanism not fully understood
- Potential interactions with opioid medications
- Inconsistent results across studies
- Long-term effects unknown
- Very limited human clinical data
- Most research from Russian institutions with limited peer review
- Long-term safety unknown
- Injection site reactions
- Theoretical concerns around telomerase activation and oncogenesis
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026 for opioid withdrawal, chronic insomnia, and narcolepsy indications. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Most research originates from Russian institutions; limited independent Western replication. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
- Delta sleep-inducing peptide (DSIP): a review
1984 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.